Immunic, inc. reports year end 2020 financial results and highlights recent activity

New york, feb. 26, 2021 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced financial results for the year...

IMUX Ratings Summary

IMUX Quant Ranking